A Brief Chat with Rob Etherington, President & CEO of Clene, Inc.

Update: 2022-12-27

Description

In this 15-minute chat, Rob Etherington, President & CEO of Clene, Inc. (NASDAQ: CLNN) discusses the potential for nanosuspensions to improve cellular energy production and treat neurodegenerative diseases, along with Clene’s future directions.

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Leveraging AI and ML in Drug R&D: Current and Future Impacts to the Life Sciences Industry

2023-10-0341:00

LifeSci Search Podcast: Episode #1

2023-03-1737:54

Regenerative Medicine from Humacyte: Off-the-Shelf, Human-Sourced Acellular Vessels for Traumatic Wound Repair

2023-02-1036:04

A Brief Chat with Erez Raphael, CEO of DarioHealth

2023-01-0617:41

Onconova – Developing Best-in-class Anti-cancer Agents with Multi-faceted MOAs

2023-01-0530:42

A Brief Chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc.

2023-01-0409:51

A Brief Chat with Martin Welschof, CEO of BioInvent

2023-01-0317:22

A Brief Chat with Raphi Levy, CFO of Alpha Tau Medical Ltd.

2022-12-2911:19

A Brief Chat with Amir London, CEO of Kamada Ltd.

2022-12-2813:30

A Brief Chat with Rob Etherington, President & CEO of Clene, Inc.

2022-12-2714:36

Helping the Body Help Itself with EscharEx: The Next Generation Wound-Care Therapeutic from MediWound

2022-12-1626:38

A Promising New Immune Checkpoint from Sensei Bio: VISTA

2022-12-1333:29

Turning Amino Acids into Drugs: A Novel Platform from Axcella Health

2022-12-0843:01

Lipocine Inc’s Formulation for Success: Oral Agents for CNS Disorders

2022-11-1727:01

89bio Aims to Tame NASH and Severe Hypertriglyceridemia (SHTG) with Lead Asset Pegozafermin

2022-11-1134:53

De-Risked Oncology Targets with Assets from Checkpoint Therapeutics

2022-11-0435:44

Deep Transcranial Magnetic Stimulation (Deep TMS™): BrainsWay’s Innovative and Non-Invasive Therapy for Major Depressive Disorder, Anxious Depression, OCD, and Smoking Addiction

2022-10-2042:11

An Oncology Update on CDK 2/9 Inhibition: Cyclacel Pharmaceuticals

2022-09-2935:22

Oncology on the Move—Artios: Financing Considerations for an Early Biotech

2022-09-1926:55

Fire Up the Immune System to Lead the Charge Against Cancer: Alligator Bioscience

2022-09-1526:46